Tempest Therapeutics (TPST) Equity Income (2014 - 2018)

Tempest Therapeutics has disclosed Equity Income across 5 years of filings, most recently posting -$2000.0 for Q3 2018.

• In Q3 2018, Equity Income rose 98.57% year-over-year to -$2000.0; the TTM figure through Sep 2018 stood at -$9000.0 (up 99.35% YoY), while the FY2017 annual figure was -$1.0 million, up 33.98% from the prior year.
• Equity Income came in at -$2000.0 for Q3 2018 at Tempest Therapeutics, up from -$4000.0 in the prior quarter.
• In the past five years, Equity Income ranged from a high of -$2000.0 in Q3 2018 to a low of -$668000.0 in Q4 2014.
• Average Equity Income over 5 years is -$317222.2, with a median of -$378000.0 recorded in 2015.
• Year-over-year, Equity Income tumbled 385.57% in 2015 and jumped 99.19% in 2017.
• Over 5 years, Equity Income stood at -$668000.0 in 2014, then soared by 42.37% to -$385000.0 in 2015, then climbed by 3.64% to -$371000.0 in 2016, then jumped by 99.19% to -$3000.0 in 2017, then surged by 33.33% to -$2000.0 in 2018.
• Per Business Quant data, the three most recent Equity Income figures were -$2000.0 in Q3 2018, -$4000.0 in Q2 2018, and -$3000.0 in Q4 2017.